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Background: Enhancing quality of life for people with long-term conditions by monitoring patient-reported
outcome measure scores is a key domain of health care policy. This study investigated the responsiveness of
patient-reported outcome measures for long-term conditions.
Methods: A cohort survey was conducted in 33 primary care practices and 4485 patients (1334 asthma, 567
chronic obstructive pulmonary disease, 1121 diabetes, 525 epilepsy, 520 heart failure and 418 stroke) were sent a
baseline survey containing a generic (EQ-5D) and a disease-specific measure. Baseline respondents were sent a
follow-up after 1 year. Differences in scores for each long-term condition were assessed by paired t-tests. The
relationship between scores and self-reported ‘change in health’ was assessed by analysis of variance.
Results: The baseline achieved a 38.4% response rate and the follow-up 71.5%. The only significant difference for
the EQ-5D was found for the Visual Analogue Scale in heart failure between baseline and follow-up, and for change
in health. Significant differences between baseline and follow-up scores were found on the disease-specific
measures for 1 asthma dimension and 1 stroke dimension. No significant differences were found for other
conditions. Significant differences between self-reported change in health and the disease-specific measures were
found for 4 asthma dimensions and 2 stroke dimensions.
Conclusions: Few significant differences were found between the baseline and follow up or between ‘change in
health’ and PROMs scores. This could be explained by the time frame of one year being too short for change to
occur or by the PROMs not being responsive enough to change in a primary care sample. The latter is unlikely as
the PROMs were in part chosen for their responsiveness to change. The baseline response rates may mean that the
sample is not representative, and stable patients may have been more likely to participate. If PROMs are to be used
routinely to monitor outcomes in LTCs, further research is needed to maximize response rates, to ensure that the
PROMs used are reliable, valid and sensitive enough to detect change and that the time frame for data collection is
appropriate.
Keywords: Patient-reported outcomes (PROMs), Long-term conditions (LTC), Cohort study, Health change,
Responsiveness* Correspondence: michele.peters@dph.ox.ac.uk
1Nuffield Department of Population Health, University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
© 2014 Peters et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Peters et al. Health and Quality of Life Outcomes 2014, 12:123 Page 2 of 10
http://www.hqlo.com/content/12/1/123Background
All health care systems require methods and measures
to track quality of care. Donabedian [1] suggested three
dimensions that together constitute quality of care: struc-
ture (i.e. the attributes of the setting in which care occurs),
process (i.e. giving and receiving care) and outcome (i.e.
the effects that care has on health status). In England, the
National Health Service (NHS) is increasingly interested
in focusing on patient-reported outcomes as indicators for
the quality of care [2]. Since 2009, such outcomes have
been assessed on a routine basis in four elective surgical
procedures (hip replacement, knee replacement, varicose
veins surgery and groin hernia repair) by the means of
patient-reported outcome measures (PROMs) [3].
An estimated 15.4 million of the population in England
report having at least one long-term condition (LTC) and
approximately a third report multiple LTCs [4]. A general
practice study in Scotland found that 42.2% of patients
had one or more morbidities with 23.3% having multiple
morbidities [5]. The expected trajectory of LTCs and
multimorbidities is a deterioration in quality of life [6,7].
Trajectories can vary in terms of speed of deterioration or
periods of improvement and exasperation, but generally
little is known about the speed and nature of disease
progression in LTCs. People with chronic conditions or
limiting LTCs are the most intensive users of the most
expensive health care services [8,9] and the majority of
health expenditure is for people with chronic conditions
[10]. It is believed that the number of those with LTCs,
including multimorbidity, will rise in the next few years
posing challenges to health care services [11] and lead-
ing to additional cost implications [8,12]. Enhancing
quality of life for people with LTCs by monitoring
PROMs scores is a key domain of health care policy in
England [3]. PROMs may also be important tools in
outcome assessment in other health care systems.
The role of PROMs in elective surgical procedures is
relatively straightforward as they are used to help assess
the effectiveness of single, discrete procedures in relation
to patients with fairly clearly defined problems for which
surgery is normally effective. The role of PROMs in LTCs
is far less clearly understood and more challenging to
identify. LTCs are complex to manage due to the multiple
physical, social and emotional problems they pose and a
diverse range of service providers and interventions are
involved in their management over long time lines. Often
the objectives of health and social care services are to
maintain well-being or to avoid deterioration rather than
to achieve major health gains. Nonetheless, PROMs may
present a method to gain more information on outcomes
in LTCs. The specific aim of this article is to report the
evidence of whether change in health status occurs after a
one year period in a primary care sample of people with
LTCs. The assumption that change can be assessed wasbased on two considerations: first, the NHS Outcomes
Framework’s [6] second domain refers to the possibility of
changes over time in the quality of life in LTCs and sec-
ond, the trajectory of many LTCs is a deterioration in
health status. One generic and appropriate disease-specific
PROMs were selected to assess health status.
Methods
A postal cohort survey was conducted in 33 primary
care practices from September 2010 to April 2012, with
the follow-up data being collected one year after the
baseline. In total 4485 patients with six LTCs (1334
asthma, 567 COPD, 1121 diabetes, 525 epilepsy, 520 heart
failure and 418 stroke patients) were invited into the
study. The LTCs were chosen by the Department of
Health on the basis of policy relevance and diversity of im-
pacts. The aim of the study was to evaluate the feasibility
of collecting PROMs data in LTCs. This article presents
the change in health status by means of presenting the
change scores between the baseline and follow-up PROMs
scores.
Ethics approval had been obtained through the National
Research Ethics (NRES) Committee of the Isle of Wight,
Portsmouth & South East Hampshire (now the NRES
South-Central Committee) in March 2010 and R&D ap-
proval from 20 participating Primary Care Trusts (PCTs).
The study was registered on the National Institute for
Health Research (NIHR) portfolio (UKCRN ID: 8462).
Design
The baseline survey, together with an information sheet,
was mailed from the practices with an accompanying
letter from the general practitioner. Respondents returned
the baseline survey to the research team. The follow-up
survey was mailed from the research team to baseline par-
ticipants who had given their consent for the follow-up.
All surveys were numbered to identify the respondents’
practice and to match baseline and follow-up responses.
At baseline, a ‘thank you/reminder’ letter was sent by
the practices after two weeks of the initial mailing to all
patients invited into the study. The follow-up reminder,
also sent after two weeks, was sent by the research team
and targeted at non-responders only. A Microsoft Ac-
cess database was used to manage the mailing and re-
ceipt of the surveys. Further details on the design are
reported elsewhere [13].
Setting
Thirty-three primary care practices in London (n = 18)
and the North-West of England (NW) (n = 15) took part
in the study. Thirty-two practices covered 3 LTCs and
one practice covered 2 LTCs. Ten practices provided
patients for asthma (5 in London and 5 in NW), 16 for
COPD (8 in London and 8 in NW), 10 for diabetes (5 in
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and 10 in NW), 20 for heart failure (11 in London and 9
in NW) and 19 for stroke (12 in London and 7 in NW).
The number of practices per LTC varied according to
LTC prevalence and practice size (12 were small (<5800
patients), 13 medium (5800–10,500 patients) and 8 large
(>10,500 patients)). A slightly larger number of practices
was recruited from more deprived areas (Table 1).
Participants
Eligible patients were identified through an automatic
and remote search of practices’ clinical systems. The
search was conducted by a subcontracted IT company
prior to the baseline survey and aimed to identify ap-
proximately 50% of the patients for each LTC in every
practice based on odd or even months of patients’ birth-
days. The search was based on Read codes in line with
the criteria used in the Quality and Outcomes Frame-
work (QOF) with two exceptions: patients with diabetes
needed to be 18 years of age and patients with transient
ischaemic attack(s) (TIAs) were excluded from the
stroke group. Patients were invited into the survey for
one LTC only; if they had multiple LTCs they were in-
cluded for their rarest condition. The list of patients
identified from the search was reviewed by a member of
staff (usually a GP or a nurse) to exclude any patients
who were not considered suitable to be invited into the
study. The instruction to practices was to exclude pa-
tients if invitation into the survey might cause serious
distress.
Patient-reported outcome measures (PROMs)
Both a generic PROM and appropriate disease-specific
PROMs were included in the surveys, as well as standard
demographics questions and a question on comorbidi-
ties. The follow-up survey also included a ‘change in
health’ question to ascertain how much respondents be-
lieved their health had changed over the last year (i.e.
since the administration of the baseline survey). The
‘change in health’ question was rated on a five-point
scale (much better, a little better, about the same, a little





Most deprived Q1 1 – 6496 4 4 8
Q2 6497 - 12992 4 6 10
Q3 12993 - 19488 5 1 6
Q4 19489 - 25984 4 2 6
Least deprived Q5 25985 - 32482 1 2 3
*Indices of Multiple Deprivation 2010.The generic PROM was the EQ-5D [13] which is a
measure of health status primarily designed to provide a
single-index value which represents the utility of specific
health states. It comprises 5 items (one each on mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression) and takes approximately five minutes to
complete. Items are scored on a three-point scale and a
single-index value is calculated typically with a score
range from 1 (perfect health) to 0 (death). Scores below
0 can be obtained indicating states worse than death.
The EQ-5D also includes a Visual Analogue Scale (VAS),
ranging from 0 ‘worst imaginable health state’ to 100
‘best imaginable health state’.
The disease-specific PROMs were the mini Asthma
Quality of Life Questionnaire (MiniAQLQ) [14,15], the
Clinical COPD Questionnaire (CCQ) [16,17], the Diabetes
Health Profile (DHP) [18,19]. Quality of Life in Epilepsy
(QOLIE-31) [20], Minnesota Living with Heart Failure
Questionnaire (MLHFQ) [21,22] and the Stroke Impact
Scale version 3 (SIS) [23]. Table 2 presents details on the
number of items, dimensions and scoring of each of the
disease-specific PROMs. Evidence for their use in the UK
was available, apart for the SIS. The PROMs were selected
on the basis of their psychometric properties evaluated by
review work (full details of the psychometric properties
can be found in the review for each LTC on this web-page
http://phi.uhce.ox.ac.uk/newpubs.php, accessed 13.12.12)
and licensing agreements. Licenses could be secured for
the psychometrically strongest PROMs for 4 LTCs
(asthma, epilepsy, heart failure and stroke). In COPD
and diabetes, licenses could not be secured and conse-
quently the PROMs identified as second best, in terms
of their psychometric properties, were selected for these
LTCs.
Analysis
The data were entered into SPSS version 18 and verified
by a professional data entry company. Data are only pre-
sented for participants who completed both the baseline
and follow-up questionnaires. Descriptive statistics were
used to describe the sample, PROMs scores at baseline
and follow-up and the ‘change in health’ question. The
‘change in health’ question was recoded into improvement
(i.e. much better and a little better), stable (i.e. about the
same) and deterioration (i.e. a little worse and much
worse). Levels of missing data for individual PROMs items
and PROM dimensions were assessed. No data imputation
was performed; therefore the sample size in the analyses
may be lower than the number of respondents. Changes
in the PROMs scores for respondents to both the baseline
and follow-up surveys were assessed with paired t-tests.
The relationship between PROMs change scores (=follow-
up scores- baseline scores) and self-reported change in
health (i.e. improved, stable or deteriorated) was assessed
Table 2 Description of the disease-specific PROMs
PROM/ Country of development Dimensions (n items) Score range
Mini Asthma Quality of Life Questionnaire
(mini-AQLQ) [14,15]/Canada
Total score (all 15 items), Activity limitations
(4 items) , Symptoms (5 items), Emotional
function (3 items), Environmental stimuli (3 items)
1-7 where 1 is ‘severe impairment’ and 7 is
‘no impairment’
Clinical COPD questionnaire (CCQ) [16,17]/
The Netherlands
Total score (all 10 items), Symptoms (4 items),
Functional state (4 items), Mental state (2 items)
0-6 where 0 ‘very good health status’ and 6
‘extremely poor health status’
Diabetes Health Profile (DHP) [18,19]/
United Kingdom
Psychological distress (6 items), Barriers to activity
(7 items), Disinhibited eating (5 items)
0-100 with a higher score representing higher
dysfunction
Quality of Life in Epilepsy Inventory
(QOLIE) [20]/United States NB we used 30
items as the Visual Analogue Scale was not
included
Total score (all 30 items), Overall quality of life
(2 items), Seizure/ worry (5 items), Emotional
well-being (5 items), Energy/ fatigue (4 items),
Cognitive (6 items), Medication effects (3 items),
Social function (5 items)
0-100 with higher scores reflecting better quality
of life
Minnesota Living with Heart Failure
Questionnaire (MLHFQ) [21,22]/United
States
Total score (all 21 items), Physical dimension
(8 items), Emotional dimension (5 items)
Total score 0–105, physical dimension score 0–40
and emotional dimension score 0–25. On all
dimensions a higher score means more
impairment
Stroke Impact Scale (SIS) [23]/United
States
Strength (4 items), Memory (7 items), Emotion
(9 items), Communication (7 items), Activities of
Daily Living (ADL) (10 items), Mobility (9 items),
Hand function (5 items), Handicap (8 items) ,
Physical dimension (hand function, strength,
mobility and ADL, 28 items)
0-6 where 0 ‘very good health status’ and 6
‘extremely poor health status’
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presented. Regression analysis was used to assess any
differences in mean changes scores by participant age
(age category 18–44 years served as reference category),
gender, time since diagnosis of the LTC and number of
comorbidities. The level of significance was set at p < 0.05.
Results
The baseline achieved a 38.4% response rate (n = 1721,
asthma n = 395 (30.0%), COPD n = 279 (49.2%), diabetes
n = 448 (40.0%), epilepsy n = 180 (34.0%), heart failure n =
262 (50.0%) and stroke n = 152 (36.4%)). A total of 1603
(93.1%) baseline participants consented to be followed up.
The response rate at follow-up was 71.5% (n = 1136,
asthma n = 267 (73.0%), COPD n = 187 (71.4%), diabetes
n = 321 (75.7%), epilepsy n = 104 (62.7%), heart failure
n = 155 (66.2%) and stroke n = 102 (74.5%)). Response rate
was significantly different at follow-up by LTC (p = 0.015),
age (p < 0.001), ethnicity (p = 0.008) and region (p =
0.007), with epilepsy and heart failure patients being less
likely to respond than patients with one of the other LTCs,
as were younger patients, those based in London and
those from ethnic minority backgrounds. The baseline
mean EQ-5D score was significantly lower (p < 0.001) in
non-responders to follow-up (mean 0.66, SD 0.33) than in
follow-up responders (mean 0.73, SD 0.29). Of the 1136
responders, 52.7% were male and 47.3% female (p < 0.001)
and 78.1% were aged 55 years or above. Age differed sig-
nificantly by disease, with asthma and epilepsy including a
larger proportion of younger respondents (p < 0.001).
Details of the response rates have been previously pub-
lished [13].Data quality
The rates of missing data for the baseline and follow-up
surveys are presented in Table 3. The rates of missing
data are presented as a range i.e. the item/dimension with
the lowest rate of missing data to the item/dimension with
the highest rate of missing data. A change score was com-
puted between the baseline and follow-up and missing
data rates for the change score are also presented. Overall
the rate of missing data was slightly higher at follow up
than at baseline. However, missing data rates were low for
the EQ-5D and slightly higher, although still acceptable,
for the EQ-5D VAS. The Mini-AQLQ (asthma), the CCQ
(COPD) and the DHP (diabetes) also had little missing
data, although the cumulative effect of missing data meant
that the rate of missing data of the change score between
baseline and follow up was >10% for some dimensions.
Rates of missing data were >10% for some items and
dimensions of the QOLIE (epilepsy), the MLHFQ (heart
failure) and SIS (stroke), leading to high rates of missing
data on the change score.PROMs scores
The mean PROMs scores for all LTCs are presented in
Table 4, together with the change scores. The only sig-
nificant change for the EQ-5D was found for the Visual
Analogue Scale (VAS) in heart failure between baseline
and follow-up, and for the ‘change in health’ question.
Significant differences between baseline and follow-up
scores were found on the disease-specific PROMs for 1
(of 4) asthma dimension and 1 (of 9) stroke dimension.
No significant differences were found for the 4 COPD, 3
Table 3 Rates (%) of missing data for the EQ-5D and disease-specific PROMs for the baseline and follow-up surveys
Individual Items Dimensions
LTC PROM N % missing baseline % missing
follow-up




Asthma Mini-AQLQ 15 0-3.8 0.8-6.8 5 1.1-7.1 3.4-11.7 4.1-15.0
EQ-5D 5 0.4-0.8 0.8-1.9 1 1.1 3.0 4.1
EQ-5D VAS 1 3.4 3.8 N/A N/A N/A 6.8
COPD CCQ 10 1.6-3.7 0-3.7 4 4.3-9.1 2.1-8.6 5.9-14.4
EQ-5D 5 0-1.1 1.1-2.1 1 2.1 4.8 5.3
EQ-5D VAS 1 5.0 4.4 N/A N/A N/A 7.8
Diabetes DHP 18 0-2.8 1.2-3.1 3 1.6-6.2 2.8-7.5 4.4-12.1
EQ-5D 5 0.9-2.5 1.6-2.2 1 3.4 3.7 6.2
EQ-5D VAS 1 5.0 4.4 N/A N/A N/A 7.8
Epilepsy QOLIE 31 0-27.9 1.0-30.8 8 0-42.3 2.9-50.0 2.9-61.5
EQ-5D 5 0-1.9 1.0-4.8 1 1.9 6.7 8.7
EQ-5D VAS 1 9.6 5.8 N/A N/A N/A 12.5
Heart failure MLHFQ 21 0.6-11.0 3.2-21.3 3 5.8-28.4 9.0-36.1 14.8-48.4
EQ-5D 5 0-3.9 1.9-4.5 1 4.5 7.7 11.6
EQ-5D VAS 1 2.6 5.2 N/A N/A N/A 6.5
Stroke SIS 60 2.9-23.5 2.0-22.5 10 5.9-36.3 5.9-38.2 9.8-52.9
EQ-5D 5 1.0-3.9 2.0-4.9 1 3.9 5.8 8.8
EQ-5D VAS 1 11.8 10.8 N/A N/A N/A 19.6
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disease-specific measures.
In response to the ‘change in health’ question, approxi-
mately half of the respondents reported their health to
have stayed stable in the last year, with approximately
a quarter reporting deterioration and another quarter
reporting improvement (Table 5). Reported change in
health differed significantly (p < 0.001) between condi-
tions, with COPD and heart failure respondents being
more likely to report deterioration and stroke and epilepsy
patients more likely to report improvement. Despite about
half the respondents reporting a change, a significant
relationship between health change and disease-specific
PROMs scores was found on all 4 asthma dimensions,
on all four COPD and 2 (out of 9) stroke dimensions.
Table 6 reports the significant changes, and the full set
of results including the non-significant findings are pro-
vided as a supplementary file (Additional file 1: Table S1).
Regression analysis examining demographic factors
(age and gender) and health factors (time since diagnosis
of LTC and number of comorbidities) found only three
significant relationships across all the PROMs change
scores – diabetes psychological distress dimension (ad-
justed R square = 0.042, p = 0.008); stroke EQ-5D York
Tariff (adjusted R square =0.11, p = 0.024) and stroke
memory dimension (adjusted R square 0.23, P < 0.001). In
diabetes, participants with a higher number of comorbidi-
ties were more likely to report change in psychologicaldistress (p < 0.001). In stroke, men were less likely to re-
port change on the EQ-5D than women (p = 0.002); and
on the stroke memory dimension younger people were
less likely to report change than the other 3 age groups
(all p < 0.001) and people with a higher number of comor-
bidities were more likely to report change (p = 0.015).
Discussion
PROMs are increasingly becoming part of the NHS for
monitoring LTCs and quality of life (outcomes). PROMs
may be an important tool in outcome assessment in any
health care system and changes over time could in
principle be analysed in relation to health care services re-
ceived. There are few longitudinal studies in a population-
based sample on the change of health in LTCs. In this
study, patients, with a confirmed diagnosis of one of six
LTCs, completed a generic and a disease-specific PROM
at two points in time one year apart. The cohort design
aimed to provide evidence of whether there was intra-
individual change in health status over one year. The sur-
vey included LTCs which might be expected to vary in
their trajectories over time; the natural history of condi-
tions such as COPD and heart failure being likely to de-
cline more rapidly compared to conditions such as asthma
and epilepsy which may be expected to be more stable
over long periods of time.
Differences between cohort baseline and follow-up
PROMs scores were found for single sub-scales in the
Table 4 PROMs scores and change by LTC
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
Asthma EQ-5D
York A1 tariff 255 0.83 0.84 0.01 0.00 0.02 0.23
VAS 248 73.77 74.33 0.56 −1.09 2.21 0.50
Asthma MINI-AQLQ
Symptoms 252 5.29 5.29 0.00 −0.12 0.12 0.99
Activity Limitations 240 6.08 5.92 −0.15 −0.26 −0.05 0.00
Emotional Functioning 253 5.37 5.28 −0.09 −0.23 0.05 0.21
Environmental Stimuli 255 5.30 5.24 −0.05 −0.17 0.07 0.38
Total QOL 226 5.60 5.52 −0.07 −0.17 0.02 0.13
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
COPD EQ-5D
York A1 tariff 177 0.67 0.67 0.00 −0.02 0.01 0.77
VAS 173 62.29 62.14 −0.14 −2.94 2.66 0.92
COPD CCQ
Symptoms 171 2.60 2.60 0.01 −0.14 0.16 0.92
Functional State 176 2.03 2.14 0.11 −0.03 0.25 0.12
Mental State 174 2.11 2.20 0.10 −0.09 0.29 0.32
Total QOL 160 2.22 2.28 0.06 −0.07 0.19 0.38
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
Diabetes EQ-5D
York A1 tariff 301 0.73 0.72 0.00 −0.01 0.01 0.60
VAS 296 68.16 69.76 1.60 −0.19 3.39 0.08
Diabetes DHP
Psychological distress 301 16.35 16.59 0.24 −1.09 1.57 0.72
Barriers to activity 282 22.17 22.39 0.22 −1.22 1.66 0.76
Disinhibited eating 307 30.16 30.08 −0.09 −1.71 1.54 0.92
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
Epilepsy EQ-5D
York A1 tariff 95 0.76 0.76 0.00 −0.02 0.02 0.89
VAS 91 71.40 73.59 2.20 −0.96 5.36 0.17
Epilepsy QOLIE
Seizure worry 95 64.49 65.32 0.82 −3.05 4.69 0.67
Overall QOL 79 68.26 68.58 0.32 −2.79 3.42 0.84
Emotional well-being 95 67.58 67.24 −0.34 −3.69 3.02 0.84
Energy 98 54.34 51.99 −2.35 −5.18 0.49 0.10
Cognitive 89 63.92 64.69 0.77 −2.18 3.73 0.60
Medication effects 98 62.59 61.65 −0.94 −5.67 3.80 0.70
Social function 53 79.25 79.04 −0.21 −5.14 4.73 0.93
Total QOL 40 69.92 70.13 0.22 −2.93 3.36 0.89
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
Heart failure EQ-5D
York A1 tariff 137 0.64 0.64 0.00 −0.02 0.01 0.62
VAS 145 62.20 58.67 −3.53 −6.69 −0.38 0.03
Heart failure MLHFQ
Total QOL 80 36.91 35.10 −1.81 −4.46 0.84 0.18
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Table 4 PROMs scores and change by LTC (Continued)
Physical dimension 125 18.44 18.02 −0.42 −1.62 0.77 0.48
Emotional dimension 132 7.79 7.48 −0.31 −0.99 0.36 0.36
N Baseline mean Follow-up mean Mean change Lower CI (95%) Upper CI (95%) p
Stroke EQ-5D
York A1 tariff 93 0.67 0.67 −0.01 −0.03 0.01 0.45
VAS 82 73.84 71.96 −1.88 −5.12 1.37 0.25
Stroke SIS
Strength 72 66.75 65.97 −0.78 −5.22 3.66 0.73
Hand function 76 73.22 72.17 −1.05 −3.67 1.57 0.43
Mobility 79 78.83 76.72 −2.11 −4.46 0.24 0.08
Memory 91 81.32 81.04 −0.27 −3.23 2.68 0.85
ADL 80 82.22 79.66 −2.56 −4.48 −0.65 0.01
Communication 92 86.88 85.05 −1.82 −4.26 0.61 0.14
Emotion 77 72.08 71.90 −0.18 −3.56 3.20 0.92
Handicap 48 72.20 72.92 0.72 −3.78 5.21 0.75
Physical dimension 52 78.08 76.35 −1.72 −3.67 0.23 0.08
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EQ-5D VAS for heart failure. For the majority of other
PROMs scores for these three conditions and for all
scales of COPD, diabetes and, epilepsy no changes were
observed over one year. It could be argued that even the
few significant changes observed may have arisen due to
multiple testing. This means that overall health-related
quality of life of all six conditions appeared stable over
the course of one year. There may be non-response bias,
as between 24.3% (diabetes) and 37.3% (epilepsy) of
baseline respondents did not return the follow-up ques-
tionnaire. It may be possible that respondents who dete-
riorated were less likely to participate in the follow-up.
Indeed participants who scored lower on the EQ-5D at
baseline were less likely to respond to the follow-up. It
should also be highlighted that the response rate to the
baseline survey was 38%, although this is similar to other
surveys in primary care samples [24-26]. Response to a
survey is more likely when the questionnaire is shorter
[27] and there may be fewer missing data meaning itTable 5 Self-reported health change after one year
Improvement Stable Deterioration
n % n % n %
Asthma 70 26.7 142 54.2 50 19.1
COPD 30 16.5 79 43.4 73 40.1
Diabetes 73 23.9 181 59.3 51 16.7
Epilepsy 30 30.0 58 58.0 12 12.0
Heart failure 24 15.7 76 49.7 53 34.6
Stroke 35 35.4 48 48.5 16 16.2
Total 262 23.8 584 53.0 255 23.2becomes feasible to calculate a score as suggested for
the SIS [28]. It may be possible that non-responders to
the baseline had lower health status, similarly to the
non-responders to the follow-up. In elective surgery,
people who were less well pre-operatively were less likely
to complete PROMs [29].
No data imputation was performed for several reasons.
For the EQ-5D and three of the disease-specific PROMs
(asthma, diabetes and COPD) the rate of missing data
was negligible and therefore data imputation was not ne-
cessary. Data imputation methods were not specified by
the developers of the PROMs for the QOLIE (epilepsy)
and the MLHFQ (heart failure). Stroke had clear guidance
on data imputation methods and a high rate of missing
data on some items; and consequently data imputation
was performed for stroke but imputation did not make a
significant difference to the findings (details available in
the full report [30]). The main reason to not impute the
data was the primary goal of the study, i.e. the study aimed
to evaluate the feasibility of collecting PROMs data in
LTCs, including the degree of completion of the adminis-
tered PROMs. Therefore the rate of missing data is con-
sidered a finding in itself and is another indicator as to the
suitability of these PROMs for the collection of PROMs
data for LTCs through primary care.
It is possible that the absence of change over time in
some of the LTCs is due to the PROMs used not being
responsive enough to detect change. There is broad agree-
ment on the psychometric properties that a PROM should
demonstrate [31]. Using PROMs to monitor outcomes in
LTCs can only be successful if PROMs are able to detect
health change or in other words the PROMs are respon-
sive to change. It seems unlikely that the PROMs used in
Table 6 Significant relationships between PROMs mean change scores and self-reported ‘change in health’
PROM dimensions Change in health N Mean change score 95% CI p
Lower Upper
Asthma
Symptoms Improvement 66 0.42 0.23 0.62 <0.001
Stable 136 −0.03 −0.17 0.12
Deterioration 48 −0.52 −0.85 −0.18
Activity Limitations Improvement 66 0.12 −0.05 0.29 <0.001
Stable 131 −0.11 −0.23 0.01
Deterioration 41 −0.74 −1.07 −0.40
Emotional Functioning Improvement 68 0.32 0.06 0.58 <0.001
Stable 136 −0.11 −0.28 0.06
Deterioration 47 −0.60 −0.98 −0.22
Environmental Stimuli Improvement 67 0.29 0.06 0.53 <0.001
Stable 139 −0.12 −0.28 0.03
Deterioration 46 −0.35 −0.65 −0.04
Total Quality of Life Improvement 62 0.27 0.10 0.43 <0.001
Stable 126 −0.09 −0.21 0.02
Deterioration 36 −0.60 −0.88 −0.32
COPD
Symptoms Improvement 30 −0.34 −0.77 0.09 0.03
Stable 72 −0.05 −0.26 0.16
Deterioration 66 0.22 −0.03 0.47
Mental Improvement 28 −0.50 −0.99 −0.01 <0.001
Stable 73 −0.01 −0.27 0.26
Deterioration 69 0.41 0.08 0.73
Functional State Improvement 29 −0.41 −0.73 −0.10 0.001
Stable 73 0.07 −0.08 0.22
Deterioration 70 0.33 0.07 0.60
Total QOL Improvement 28 −0.42 −0.75 −0.08 <0.001
Stable 66 −0.02 −0.17 0.13
Deterioration 63 0.32 0.09 0.55
Stroke
Hand Function Improvement 27 1.11 −2.06 4.28 0.048
Stable 37 −0.27 −4.35 3.81
Deterioration 12 −8.33 −16.94 0.27
ADL Improvement 29 0.00 −1.82 1.82 0.042
Stable 38 −3.03 −6.09 0.04
Deterioration 12 −7.29 −14.76 0.17
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disease-specific instruments are more likely to be sensitive
and therefore more responsive to change in comparison to
generic measures. In this study disease-specific PROMs
were more likely than the generic EQ-5D to detect a
change in the case of asthma and COPD, when compared
to patients’ retrospective judgements of health change ofthe last year. Extensive review work summarised evidence
on responsiveness for the majority of the disease-specific
PROMs including the MiniAQLQ for asthma [32], the
DHP for diabetes [33], the QOLIE-31 for epilepsy [34] and
the MHLFQ for heart failure [35]. The PROMs used had
been selected on the basis of extensive review work and
responsiveness was one amongst a range of psychometric
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reviews, information on responsiveness was available
for the majority of the instruments; however the evi-
dence was more mixed and/or limited for COPD
(CCQ) [36] and stroke (SIS) [37]. The EQ-5D has been
shown in previous studies to be responsive to change,
although either the time periods for follow-up were
longer [38,39], participants were at a more advanced
stage of disease at the time of the study [40,41], partici-
pants were hospitalized [42] or had been given a drug
intervention [43].
For all LTCs, in response to a simple retrospective
health change question about their LTC compared
to a year before, substantial proportions of respon-
dents reported improvement (23.8%) or deterioration
(23.2%), with individuals with COPD (40%) particu-
larly likely to notice deterioration, compared with
respondents with diabetes and epilepsy who were
more likely to view their condition as stable (59.3%
and 58.0% respectively). Stroke respondents were
the most likely to have experienced improvement
(35.4%). The majority of the respondents reported
their health to have stayed stable over the period of
one year. This may be an indication that a period of
one year is not long enough to identify changes
in health status. Given the more limited scope for
improvement compared with the dramatic improve-
ment in health status observed via PROMs for elect-
ive orthopaedic surgical procedures, more work is
needed to gain evidence on the rate of deterioration
and trajectory (such as slow vs. rapid deterioration,
periods of stability and exacerbations) and to identify
health changes that are meaningful for PROMs for
LTCs in diagnosed validated samples. To our know-
ledge, there is currently little evidence via condition-
specific PROMs for primary care.Conclusions
Few significant differences were found between the
baseline and follow up surveys or between self-
reported change in health and PROMs scores. This
could be explained by the time frame of one year
being too short for change to occur or by the
PROMs not being responsive enough to change in a
primary care sample. Currently, little is known about
speed of progression of various LTCs particularly in
relation to health-related quality of life. If PROMs
are to be used routinely to monitor outcomes in
LTCs, further research is needed to ensure that
the PROMs used are reliable, valid and sensitive
enough to detect change and that the time frame for
data collection is appropriate for change to have
occurred.Additional file
Additional file 1: Table S1. Relationships between mean change in
PROM scores and self-reported ‘change in health’ question.
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